Hyper-interleukin-6 which stimulates nerve cells to regenerate makes paralyzed mice walk again

To date, paralysis resulting from spinal cord damage has been irreparable. With a new therapeutic approach, scientists from the Department for Cell Physiology at Ruhr-Universität Bochum (RUB) headed by Professor Dietmar Fischer have succeeded for the first time in getting paralyzed mice to walk again.

The keys to this are the protein hyper-interleukin-6, which stimulates nerve cells to regenerate, and the way how it is supplied to the animals. The researchers published their report in the journal Nature Communications from 15 January 2021.

Spinal cord injuries caused by sports or traffic accidents often result in permanent disabilities such as paraplegia.

This is caused by damage to nerve fibers, so-called axons, which carry information from the brain to the muscles and back from the skin and muscles.

If these fibers are damaged due to injury or illness, this communication is interrupted.

Since severed axons in the spinal cord can’t grow back, the patients suffer from paralysis and numbness for life. To date, there are still no treatment options that could restore the lost functions in affected patients.

Designer protein stimulates regeneration

In their search for potential therapeutic approaches, the Bochum team has been working with the protein hyper-interleukin-6. “This is a so-called designer cytokine, which means it doesn’t occur like this in nature and has to be produced using genetic engineering,” explains Dietmar Fischer.

His research group already demonstrated in a previous study that hIL-6 can efficiently stimulate the regeneration of nerve cells in the visual system.

In their current study, the Bochum team induced nerve cells of the motor-sensory cortex to produce hyper-Interleukin-6 themselves. For this purpose, they used viruses suitable for gene therapy, which they injected into an easily accessible brain area.

There, the viruses deliver the blueprint for the production of the protein to specific nerve cells, so-called motoneurons. Since these cells are also linked via axonal side branches to other nerve cells in other brain areas that are important for movement processes such as walking, the hyper-interleukin-6 was also transported directly to these otherwise difficult to access essential nerve cells and released there in a controlled manner.

Applied in one area, effective in several areas

“Thus, gene therapy treatment of only a few nerve cells stimulated the axonal regeneration of various nerve cells in the brain and several motor tracts in the spinal cord simultaneously,” says Dietmar Fischer.

“Ultimately, this enabled the previously paralyzed animals that received this treatment to start walking after two to three weeks. This came as a great surprise to us at the beginning, as it had never been shown to be possible before after full paraplegia.”

The research team is now investigating to what extent this or similar approaches can be combined with other measures to optimize the administration of hyper-Interleukin-6 further and achieve additional functional improvements.

They are also exploring whether hyper-interleukin-6 still has positive effects in mice, even if the injury occurred several weeks previously.

“This aspect would be particularly relevant for application in humans,” says Fischer. “We are now breaking new scientific ground. These further experiments will show, among other things, whether it will be possible to transfer these new approaches to humans in the future.”

Interleukin-6 (IL-6) is considered one of the most prominent pro-inflammatory cytokines 1. Blockade of IL-6 by the neutralising monoclonal antibody tocilizumab has been approved in more than 100 countries for the treatment of patients with autoimmune disorders such as rheumatoid arthritis 2. Additionally, the cytokine storm sometimes encountered when cancer patients are treated with chimeric antigen receptor (CAR) T-cells 3 could be effectively treated with the antibody tocilizumab, leading to US Food and Drug Administration (FDA) approval of the drug for this condition. Even more recently, it has been recognised that many patients experience a similar cytokine storm upon infection with SARS-CoV-2 (COVID-19) virus 4 and that these patients could also be treated with tocilizumab 5. These new data led to a rekindled general interest in the cytokine IL-6.

IL-6 was initially discovered and cloned in the Kishimoto laboratory as a B-cell stimulatory factor 6. Immediately after the molecular cloning, it was evident that IL-6 was identical to hepatocyte stimulating factor 7, hybridoma-plasmacytoma growth factor 8, interferon β2 9, and 26 kDa protein 10. This already indicated the pleiotropic nature of the cytokine. Later on, it was also recognised that IL-6 shows profound activities in the brain 11, 12, in the regulation of metabolism 13, 14, in the response of the body to exercise 15, and in the development and maintenance of various cancers 16.

This review article gives a short overview of the complex biology of IL-6 and explains how one cytokine can have extremely different biologic effects on different cells and in different physiologic states of the human body 17.

The interleukin-6 receptor complex
The four-helical cytokine IL-6 ( Figure 1) on cells binds to a membrane-bound IL-6 receptor (IL-6R), and the complex of IL-6 and IL-6R associates with a second receptor protein, glycoprotein 130 kDa (gp130), which dimerises and initiates intracellular signalling via the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) and rat sarcoma proto oncogene (ras)/mitogen-activated protein kinase and phosphoinositide-3 kinase pathways ( Figure 2) 18. Importantly, IL-6 exhibits only a measurable affinity to the IL-6R but not to gp130, and the IL-6R does not bind on its own to gp130. It is only the complex of IL-6 and IL-6R that binds to gp130 and induces its dimerisation ( Figure 2). All cells in the body express gp130, but only a few cells such as hepatocytes and some leukocytes express IL-6R. It follows that cells that express only gp130 but not IL-6R cannot be stimulated by IL-6 1.

Noteworthy, gp130 is a component of the receptor complexes of the so-called gp130 cytokine family, which besides IL-6 comprises IL-11, ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC), leukaemia inhibitory factor (LIF), oncostatin M (OSM), and IL-27. For details, please refer to recent reviews 19, 20.

It has, however, been noticed that the membrane-bound IL-6R can be cleaved by the membrane-bound metalloprotease a disintegrin and metalloprotease 17 (ADAM17) to generate a soluble IL-6R (sIL-6R) 21. To a minor extent, the human—but not the murine—sIL-6R can be generated by translation from a differentially spliced mRNA 22. Intriguingly, the sIL-6R can still bind IL-6, and the complex of IL-6 and sIL-6R can associate with gp130 and induce signalling, even on cells that lack the membrane-bound IL-6R 23. This process has been named IL-6 trans-signalling ( Figure 3) 24. Strikingly, following this paradigm, IL-6 can, in the presence of sIL-6R, stimulate any cell in the body since all cells express gp130 17.

Interestingly, most IL-6R-expressing cells including hepatocytes express far more gp130 than IL-6R molecules. Therefore, stimulation of such cells with IL-6 alone will only lead to engagement of few gp130 molecules, whereas stimulation with the complex of IL-6 and sIL-6R will stimulate all cellular gp130 proteins. A threshold for a given response might not be reached with IL-6 stimulation but only with stimulation of all gp130 molecules via IL-6 trans-signalling. This might be an explanation for the observed differences in signalling between trans-signalling and classical signalling that lead to different phenotypes 25.

Molecular tools to elucidate the functions of interleukin-6
The concept of IL-6 trans-signalling has been corroborated by the use of two designer proteins. The first such protein consists of IL-6 covalently fused to the sIL-6R via a 40 Å flexible peptide linker, which allowed the placement of IL-6 at the correct distance to reach the IL-6 binding site of the sIL-6R. This protein was called Hyper-IL-6 ( Figure 3A) 26. This protein was shown to stimulate gp130-expressing cells in vitro and in vivo, and it was shown that liver regeneration 27, stimulation of neural cells 28, and expansion of hematopoietic cells 29 was far more efficient in the presence of Hyper-IL-6 as compared to IL-6 alone 30.

While Hyper-IL-6 demonstrated only the biologic potential of IL-6 trans-signalling, these experiments did not prove that this process occurred in vivo. A second soluble protein was designed, which consisted of the entire extracellular portion of gp130 covalently fused to the Fc region of human IgG1 ( Figure 3B). The resulting protein, named soluble gp130Fc (sgp130Fc), turned out to exhibit similar properties as membrane-bound gp130: it did not bind IL-6 or IL-6R alone, but it bound with high affinity the complex of IL-6 and sIL-6R 31, 32. Consequently, the sgp130 protein in vitro and in vivo specifically inhibited IL-6 trans-signalling without compromising IL-6 signalling via the membrane-bound IL-6R, i.e. classic signalling 32. The sgp130Fc protein could be used to define IL-6-mediated biologic responses, which were dependent on classic or trans-signalling. This was accomplished by comparing the treatment of animals with sgp130Fc or with neutralising antibodies against IL-6 or IL-6R, which blocked all IL-6 signalling ( Figure 3C, D). Using animal models of human inflammatory diseases or inflammation-associated cancer, it turned out that autoimmune disorders and inflammation-associated cancers were mainly driven by IL-6 trans-signalling whereas regenerative and protective activities of IL-6 were mediated by classic IL-6 signalling via the membrane-bound IL-6R ( Figure 4) 20.

Physiologic and pathophysiologic functions of interleukin-6
Under homeostatic conditions, IL-6 levels in the circulation are as low as 1–5 pg/ml, but during inflammatory states these levels can rise more than 1,000-fold, and under extreme conditions leading to sepsis IL-6 levels in the µg/ml range have been reported 33. IL-6 is produced by myeloid cells upon Toll-like receptor stimulation together with the cytokines IL-1β and tumor necrosis factor α (TNFα), which, via a feed-forward loop, lead to an immense amplification of IL-6 production during inflammatory conditions 34. There is perhaps no other protein in the human body whose level can go up by six orders of magnitude. This lets us conclude that IL-6 is the major alarm signal in the human body in response to infection, inflammation, and possibly cancer 35.

However, under normal conditions, IL-6 plays an important role in organ/cellular homeostasis. Mice in which the IL-6 gene has been ablated (IL-6 knockout mice) become obese late in life 13, cannot regenerate their liver upon hepatectomy 36, and show no signs of osteoporosis upon ovariectomy 37, indicating roles for IL-6 in body weight regulation, liver physiology, and bone metabolism. In pathophysiologic states, however, there are marked differences between IL-6 knockout mice and wild-type mice. IL-6 knockout mice are completely protected in animal models of rheumatoid arthritis 38 and multiple sclerosis 39, indicating a key role for IL-6 in these autoimmune disorders.

With the help of the sgp130Fc protein and of neutralising monoclonal antibodies, it was possible to selectively block IL-6 trans-signalling or to block all IL-6 signalling, respectively. Using this approach, it was shown that classic IL-6 signalling via the membrane-bound IL-6R was responsible for the defence of the body against bacteria 40, 41, intestinal regeneration upon polymicrobial sepsis 42, prevention of aortic rupture in animal models of abdominal aortic aneurysm 43, and healing of bone fractures 44, 45, indicating that these important processes are severely compromised under blockade of global IL-6 activity 46. It has been hypothesised that the same might apply for the treatment of COVID-19 patients 46 ( Figure 4).

Besides being the major alarm signal in the human body, IL-6 plays a dominant role in various types of cancer. One important reason could be that IL-6, via stimulation of the STAT3 pathway, is a prominent growth factor of many cancer cells. The following scenario has been worked out in pancreatic cancer 47. It was noted that in the Kras G12D model, the massive activation of the STAT3 pathway, which led to tumour progression, was induced by tumour-infiltrating myeloid cells, which stimulated the neoplastic cells via IL-6 trans-signalling 47. Selective blockade of this pathway by the sgp130Fc protein blocked progression of pancreatic intraepithelial neoplasias to pancreatic ductal adenocarcinomas 47, indicating a prominent role for IL-6 trans-signalling in the development of pancreatic cancer. In the murine APC min/+ model of colon cancer, it was established that the genetic deletion of ADAM17, which is responsible for generating not only sIL-6R but also soluble TNFα and soluble ligands of the epidermal growth factor receptor (EGFR), resulted in completely abrogated tumour development 16. Moreover, the formation of neoplasias stimulated ADAM17 on macrophages, leading to EGFR ligand cleavage and subsequent EGFR stimulation. These macrophages now produced IL-6 and sIL-6R, which led to the outgrowth of the tumours. Again, selective blockade of the IL-6 trans-signalling pathway by the sgp130Fc protein blocked tumour development in the APC min/+ model and an additional mouse model of colon cancer 16. This was highly reminiscent of a study in liver cancer, in which it was shown that the EGFR expressed in macrophages but not EGFR in hepatocytes was involved in the development of hepatocellular carcinoma 48. Apparently, macrophage activation may be an important step in the initiation and progression of tumours via the IL-6 trans-signalling pathway 20 ( Figure 4).

Therapeutic targeting of interleukin-6 activity
Therapeutic targeting of the pro-inflammatory cytokine TNFα was introduced as an efficient strategy to treat patients with autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease 49. Subsequently, blockade of the biologic activity of the cytokine IL-6 was shown to be an efficient treatment for patients with rheumatoid arthritis and other autoimmune diseases 2, and it was shown that blocking IL-6 activity was more efficient than blocking TNFα in a monotherapy trial 50. Blockade of IL-6 activity with the IL-6R neutralising monoclonal antibody tocilizumab was also highly effective in the treatment of patients with CAR T cell-induced severe cytokine release syndrome 51. In patients with severe COVID-19 disease, the administration of tocilizumab resulted in a marked improvement of the condition in the majority of patients: the fever subsided, C-reactive protein decreased, and oxygen intake could be lowered. No obvious adverse reactions were observed. These preliminary data indicated that tocilizumab is a candidate for effective treatment of COVID-19 patients 5, 52. Interestingly, treatment of COVID-19 patients with the IL-6R neutralising monoclonal antibody sarilumab resulted in no significant difference in clinical improvement and mortality 53.

Summary
The discovery that the pro-inflammatory activities of IL-6 are mediated by IL-6 trans-signalling whereas the protective and regenerative activities of IL-6 rely on classic signalling via the membrane-bound IL-6R suggested that the sgp130Fc protein might be an ideal candidate for a more specific mode of cytokine blockade as opposed to global cytokine inhibition 20. It was shown in appropriate animal models that blockade of IL-6 trans-signalling was indeed superior to global IL-6 blockade in a bone healing model 44, 45, in a sepsis model 42, in abdominal aortic aneurysm models 43, and in bacterial infection models 40, 41. The sgp130Fc protein was expressed and purified according to GMP regulations. Phase I clinical trials were successfully performed with healthy individuals, and a phase II clinical trial is presently ongoing in patients with inflammatory bowel disease 54. The future will tell whether this elegant therapeutic approach, which was successfully tested in many animal models, leads to a novel paradigm in cytokine-blocking therapies in patients with autoimmune disorders 46. Similarly, blockade of trans-signalling while leaving classical signalling intact may prove to be beneficial for patients experiencing “cytokine storms” from COVID-19 or CAR T-cell therapies. Finally, we suggest that malignancies promoted by high levels of trans-signalling could be contained by this therapeutic modality.

reference link : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443778/

More information: Marco Leibinger et al. Transneuronal delivery of hyper-interleukin-6 enables functional recovery after severe spinal cord injury in mice, Nature Communications (2021). DOI: 10.1038/s41467-020-20112-4